Skip to main content
Fig. 6 | Breast Cancer Research

Fig. 6

From: Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer

Fig. 6

Effect of RAD001 (RAD) and neratinib (Ner) alone or in combination with endocrine therapy in vivo. a Long-term study assessing the relative mean changes in tumour volume over 41 days of treatment and b effect of drug regimes on animal weight. Error bars represent mean ± SEM (n = 7–9 animals per group). RAD001, 2 mg/kg; neratinib, 40 mg/kg; fulvestrant (ICI), 5 mg/kg. c–f GSEA enrichment plots for 198 genes known to be induced by sustained activation of ERK in response to EGF activity. Plots show the profile of the running Enrichment Score and positions of GeneSet Members on the Rank Ordered List for rank gene lists generated from the comparison of c neratinib vs. vehicle (Veh), d RAD001 vs. vehicle, e RAD001 + neratinib vs. RAD001, and f RAD001 + neratinib + ICI vs. RAD001 + neratinib

Back to article page